Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

/PRNewswire/ — Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499…
Share This Post
Related Articles
Receive the latest updates

Subscribe To
Our Quarterly Newsletter

Get notified about new blog posts, case studies, white papers, and more!